# Standard Regulatory Terminology

## General Terms

| Preferred Term | Avoid | Definition | Context |
|----------------|-------|------------|---------|
| Medical device | Product, equipment, item | Instrument, apparatus, or article intended for medical purposes | ISO 13485, EU MDR |
| Manufacturer | Company, vendor, supplier | Legal entity responsible for design, manufacture, packaging, and labeling | 21 CFR 820, ISO 13485 |
| Intended use | Purpose, function, indication | Use for which a device is intended according to labeling | EU MDR Article 2(12) |
| Intended purpose | Goal, objective | Same as intended use (EU terminology) | EU MDR preferred term |
| User | Operator, customer, patient | Person using the device | IEC 62366-1 |
| Patient | Subject, individual | Person receiving medical treatment | Clinical evaluation context |

## Risk Management Terms

| Preferred Term | Avoid | Definition | Source |
|----------------|-------|------------|--------|
| Hazard | Danger, threat | Potential source of harm | ISO 14971:2019 |
| Risk | Danger level, safety concern | Combination of probability and severity of harm | ISO 14971:2019 |
| Severity | Impact, consequence | Measure of possible consequences of a hazard | ISO 14971:2019 |
| Probability | Likelihood, chance | Measure of likelihood of occurrence | ISO 14971:2019 |
| Risk management | Risk assessment | Systematic application of policies, procedures, and practices | ISO 14971:2019 |
| Residual risk | Remaining risk, leftover risk | Risk remaining after risk control measures | ISO 14971:2019 |
| Risk control | Risk mitigation, risk reduction | Measures to reduce risk | ISO 14971:2019 |
| Risk-benefit analysis | Benefit-risk, risk vs benefit | Comparison of residual risk to expected benefits | ISO 14971:2019 |

## Quality Management Terms

| Preferred Term | Avoid | Definition | Source |
|----------------|-------|------------|--------|
| Quality management system (QMS) | Quality system | Management system to direct and control quality | ISO 13485:2016 |
| Design control | Design process, development | Application of systematic measures to design process | 21 CFR 820.30 |
| Design verification | Testing, checking | Confirmation by examination and objective evidence | ISO 13485:2016 |
| Design validation | User testing, field testing | Confirmation that requirements for intended use are met | ISO 13485:2016 |
| Change control | Change management | Systematic approach to managing changes | ISO 13485:2016 |
| Nonconformity | Defect, issue, problem | Non-fulfillment of a requirement | ISO 13485:2016 |
| Corrective action | Fix, correction | Action to eliminate cause of nonconformity | ISO 13485:2016 |
| Preventive action | Proactive measure | Action to eliminate cause of potential nonconformity | ISO 13485:2016 (deprecated in ISO 9001:2015) |
| CAPA | Corrective/preventive action | Combined corrective and preventive actions | 21 CFR 820.100 |

## Design and Development Terms

| Preferred Term | Avoid | Definition | Source |
|----------------|-------|------------|--------|
| Design input | Requirement, specification | Requirements for device design | 21 CFR 820.30(c) |
| Design output | Deliverable, result | Results of design process | 21 CFR 820.30(d) |
| Design review | Design meeting, review session | Formal review of design results | 21 CFR 820.30(e) |
| Design transfer | Handoff, transition | Transfer of design to manufacturing | 21 CFR 820.30(h) |
| Design history file (DHF) | Design records | Collection of design documentation | 21 CFR 820.30(j) |
| Device master record (DMR) | Manufacturing specs | Compilation of manufacturing procedures | 21 CFR 820.181 |
| Device history record (DHR) | Production record | Record of manufacturing for each batch | 21 CFR 820.184 |

## Clinical and Performance Terms

| Preferred Term | Avoid | Definition | Source |
|----------------|-------|------------|--------|
| Clinical evaluation | Clinical assessment | Assessment of clinical data | EU MDR Annex XIV |
| Clinical investigation | Clinical trial, study | Systematic investigation on humans | EU MDR Article 2(45) |
| Essential performance | Key function, critical function | Performance necessary to avoid unacceptable risk | IEC 60601-1 |
| Performance evaluation | Performance testing | Assessment of performance claims | IVDR Article 56 |
| Post-market surveillance (PMS) | Post-launch monitoring | Proactive collection and review of experience | EU MDR Article 83 |
| Post-market clinical follow-up (PMCF) | Follow-up study | Ongoing process to collect clinical data | EU MDR Article 2(61) |
| Vigilance | Adverse event monitoring | System for reporting incidents | EU MDR Article 87 |

## Regulatory Pathway Terms

| Preferred Term | Avoid | Definition | Region |
|----------------|-------|------------|--------|
| 510(k) premarket notification | 510k, premarket clearance | FDA pathway for substantial equivalence | FDA (US) |
| Premarket approval (PMA) | PMA application | FDA pathway for Class III devices | FDA (US) |
| De novo classification | De novo review | FDA pathway for novel low-moderate risk devices | FDA (US) |
| Conformity assessment | CE marking process | Process to demonstrate MDR compliance | EU |
| Notified Body | NB, certification body | Organization designated to assess conformity | EU |
| Technical documentation | Tech file, technical dossier | Documentation demonstrating conformity | EU MDR Annex II/III |
| Class I/IIa/IIb/III | Risk class, device class | EU device classification | EU MDR Annex VIII |

## Usability Terms

| Preferred Term | Avoid | Definition | Source |
|----------------|-------|------------|--------|
| Usability | User-friendliness, ease of use | Extent to which users can achieve goals effectively | IEC 62366-1:2015 |
| Use error | User error, mistake | Act or omission resulting in different result than intended | IEC 62366-1:2015 |
| Use scenario | Use case, task | Specific intended use in specific context | IEC 62366-1:2015 |
| Formative evaluation | Formative testing | Usability testing during development | IEC 62366-1:2015 |
| Summative evaluation | Validation testing | Final usability validation | IEC 62366-1:2015 |
| Human factors | Ergonomics, user experience | Application of knowledge about human behavior | IEC 62366-1:2015 |

## Abbreviations (Use Sparingly)

Define all abbreviations on first use.

**Format:** "Full term (abbreviation)"

**Example:** "Quality Management System (QMS)"

### Commonly Accepted Abbreviations

- **QMS**: Quality Management System
- **DHF**: Design History File
- **DMR**: Device Master Record
- **DHR**: Device History Record
- **CAPA**: Corrective and Preventive Action
- **PMS**: Post-Market Surveillance
- **PMCF**: Post-Market Clinical Follow-up
- **IFU**: Instructions for Use
- **UDI**: Unique Device Identifier

### Abbreviations to Avoid

Do not abbreviate these terms in formal regulatory documents:
- Risk management (not RM)
- Design verification (not DV)
- Design validation (not DVal)
- Essential performance (not EP)
- Intended use (not IU)

## Region-Specific Terminology

### US (FDA) Terms

- Premarket notification (510(k))
- Premarket approval (PMA)
- Investigational Device Exemption (IDE)
- Establishment registration
- Device listing

### EU (MDR/IVDR) Terms

- Notified Body
- Conformity assessment
- Technical documentation
- Declaration of conformity
- Authorized representative

### International (ISO) Terms

- Quality management system
- Risk management file
- Design and development
- Verification and validation
- Monitoring and measurement

## Terminology Consistency Checklist

When reviewing documents:

- [ ] Single term used consistently throughout (not synonyms)
- [ ] Region-appropriate terminology (FDA vs EU vs ISO)
- [ ] Abbreviations defined on first use
- [ ] Standard regulatory terms per this list
- [ ] No colloquial or promotional language
- [ ] Terms match cited regulation language
